helped by the company's buyback has turned positive after a complicated year. Despite this in terms of foundamentals two drugs are on the way to be developped but such developments will be revealed in the next year so patient is a must for those who wants to invest of something concreate. On a technical point of view yesterday price faild to cross MA 200. This is an importante resistence and a tp for those who bought shares in the last weeks as the RSI
is overbought, thus a little pullback is expected in the next days.
Levels to watch are the followings as reported: 89.20, 86.27.